Testing a new version of a bone health injection
Part of Bones, joints & muscles, Hormones & metabolism clinical trials.
This study tests a new version of a medicine called abaloparatide (used for bone health) to see if it works the same as the approved version (Tymlos). It is for healthy adults aged 40–65 who are willing to stay at the clinic for a few days and have blood tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 40 and 65 years old.
- You must be generally healthy, without serious heart, liver, kidney, or other chronic conditions.
- Your body mass index (BMI) should be between 19 and 28, and you must meet minimum weight (50 kg for men, 45 kg for women).
- You cannot have high blood calcium, gout, kidney stones, or a history of bone radiation therapy.
- You must be willing to avoid pregnancy (or sperm donation) and use effective birth control for 6 months after the study.
- You cannot have taken certain medicines, supplements, or herbal products within the past 1–2 weeks, or have a history of drug or alcohol abuse.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called SAL023 to see how it compares to an approved drug (Evenity) in healthy people. It looks at how the body processes the drug, safety, and immune response. You must be healthy, within a certain age and weight range, and not have any bone or heart problems.
This study is a follow-up for people who completed a previous precision medicine trial for osteoporosis. It will monitor your bone health to see how well the treatment is working over time.
This study tests two injectable medications (romosozumab and abaloparatide) that help strengthen bones in women after menopause. Researchers will also look at blood markers to understand why some women respond better to treatment than others.
This study tests a medication called tirzepatide (a type of GLP-1 drug) to see how it affects muscle and bone health during weight loss. It is for people with obesity who are not menopausal and do not have diabetes or bone disease.
This trial studies AGN1 LOEP, a treatment being tested to improve bone strength in people with osteoporosis-related bone loss in the hip. If you qualify, you would be followed over time with clinic visits and testing to see how the treatment affects your bone health.
This trial tests whether switching between two medications (Romosozumab and Denosumab) using a cycle or sequence schedule works better for improving bone density in postmenopausal women with severe osteoporosis. It aims to find the most effective treatment plan.
Hear when a new Osteoporosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.